ProQR shared additional analyses from the Phase 2/3 Illuminate trial of sepofarsen for LCA10 and provided an update on the company strategy. Management to host a conference call today at 8:00am EDT (14:00 CET).
Company management will participate in the Cantor Virtual Rare Orphan Disease Summit on March 29 as part of the RNA Therapeutics in Rare Diseases panel from 2:45-3:45pm EDT.